- Home
- GPRK vs ETON Comparison
GPRK vs ETON Comparison
Compare GPRK & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | ETON |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 411.9M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GPRK | ETON |
|---|---|---|
| Price | $8.77 | $18.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.50 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 724.3K | 291.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,011,000.00 |
| Revenue This Year | N/A | $107.23 |
| Revenue Next Year | $23.25 | $29.72 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $5.66 | $11.09 |
| 52 Week High | $9.09 | $23.00 |
Technical Indicators
Market Signals| Indicator | GPRK | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 64.96 |
| Support Level | $7.84 | $16.04 |
| Resistance Level | $9.09 | $20.01 |
| Average True Range (ATR) | 0.37 | 1.08 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 69.10 | 70.56 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.